Toxicity of cytostatic drugs to normal bone marrow cells in vitro

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 1, 1998, Pages 17-23

  Sundman Engberg, Britt ^a   Tidefelt, Ulf ^b   Paul, Christer ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

AMSA; Anthracyclines; Ara C; Human CFU GM

Indexed keywords

ACLARUBICIN; AMSACRINE; ANTHRACYCLINE; CYTARABINE; CYTOSTATIC AGENT; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; JACLACIN; MITOXANTRONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW CELL; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CHILD; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; INCUBATION TIME; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AMSACRINE; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELLS, CULTURED; CHILD; COLONY-FORMING UNITS ASSAY; CYTARABINE; DOXORUBICIN; HUMANS; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 0031954909     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050779     Document Type: Article

References (28)

1. Ajani JA, Blaauw AA, Spitzer G, Baker FL, Tomasovic B, Umbach G, Thielvoldt D, Zander AR, Dicke KA (1985) Differential cytotoxic activity of chemotherapy agents on colonyforming cells from human tumors and normal hone marrow in vitro. Exp Hematol 13: 95 100
2. Böyum A (1968) Isolation of leukocytes from human blood. Further observations. Methylcellulose, dextran and Ficoll as erythrocyte aggregating agents. Scand J Clin Lab Invest 21 [Suppl 97]: 31 50
3. Crespi MD, Ivanier SE, Genovese J, Baldi A (1986) Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem Biophys Res Commun 136: 521 528
4. Iseove NN, Senn JS, Till JE, et al (1971) Colony formation by normal and leukemic human marrow cells in culture. Effect of conditioned medium from human leukocytes. Blood 37: 1 5
5. Jensen PB, Sörensen BS, Sehested M. Demant EJ, Kjeldsen E, Friche E, Hansen HH (1993) Different modes of anthracyeline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 45: 2025 2035
6. Legha SS, Benjamin RS, Mackay B, Ewer E, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96: 133 139
7. Liliemark J, Plunketrt W (1986) Regulation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in human leukemia cells by deoxycytidine 5′-triphosphate. Cancer Res 46: 1079-1083
8. Liliemark J, Gahtron G, Paul C, Peterson C (1987) Ara-C in plasma and Ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of Ara-C in patients with acute nonlymphoblastic leukemia. Semin Oncol 14: 167 171
9. Liu LF (1983) DNA topoisomerases enzymes that catalyse the breaking and rejoining of DNA. CRC Crit Rev Biochem 15: 1 24
10. Nagler A, Kletter Y, Ricklis I, Gazit E, Tatarsky I, Fabian I (1986) Effect of cytosine arabinoside on differentiation of normal human bone marrow cells. Exp Hematol 14: 241 245
11. Park CH, Amare M, Salvin MA, Goodwin JW, Newcomb MM, Hoogstraten B (1980) Prediction of chemotherapy response in human leukemia using an in vitro chemotherapy sensitivity test on the leukemic colony-forming cells. Blood 55: 595-601
12. Paul C, Liliemark J, Tidefelt U, Gahrton G, Peterson C (1989) Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther Drug Monit 11: 140 148
13. Paul C, Tidefelt U, Liliemark J, Peterson C (1989) Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time. Leuk Res 13: 191 196
14. Raijmakers R, Witte T de, Linssen P, Wessels J, Haanen C (1986) The relation of exposure time and drug concentration in their effect on cloning efficiency after incubation of human bone marrow with cytosine arabinoside. Br J Haematol 62: 447-453
15. Raijmakers A, Speth P, Witte T de, Linssen P, Wessels J, Haanen C (1987) Infusion-rate dependent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM). Br J Cancer 56: 123 126
16. Rhedin AS, Tidefelt U, Jönsson K, Lundin A, Paul C (1993) Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk Res 17: 271-276
17. Seargeant LE, Kobrinsky NI, Sus CJ, Nazeravich DR (1987) In vitro stability and compatibility of daunorubicin, cytarabine and etoposide. Cancer Treat Rep 71: 1189 1192
18. Spiro TE, Mattelaer A-M, Efira A, Stryckmans P (1981) Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. J Natl Cancer Inst 66: 1053-1059
19. Spiro TE, Socquet M, Delforge A, Stryckmans P (1981) Chemotherapeutic sensitivity of normal and leukemic hematopoietic progenitor cells to n-[4-(9-acridinylamino)-3-methophenyl]-methanesulfonamide, a new anticancer agent. J Natl Cancer Inst 66: 615-618
20. Sundman-Engberg B, Tidefelt U, Liliemark J, Paul C (1990) Intracellular concentrations of anticancer drugs in leukemic cells in vitro versus in vivo. Cancer Chemother Pharmacol 25: 252-256
21. Sundman-Engberg B, Tidefelt U, Gruber A, Paul C (1993) Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo. Leuk Res 17: 347-352
22. Suzuki H, Kawashima K, Jamada K (1979) Aclacinomycin A, a new antileukemic agent (letter). Lancet L: 870-871
23. Tannock IF (1986) Experimental chemotherapy and concepts related to the cell cycle. Int J Radiat 149: 335-355
24. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycininduced DNA damage by mammalian DNA topoisomerase II. Science 226: 466-468
25. Tidefelt U, Sundman-Engberg B, Paul C (1989) Comparison of the intracellular pharmacokinetics of doxorubicin and 4-epidoxorubicin in patients with acute leukemia. Cancer Chemother Pharmacol 24: 225-229
26. Tidefelt U, Sundman-Engberg B, Rhedin A-S, Paul C (1989) In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations. Eur J Hematol 43: 374-389
27. Tidefelt U, Prenkert M, Paul C (1996) Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells. Cancer Chemother Pharmacol 38: 476-480
28. Umbach GE, Hug V, Spitzer G, Tomasovic B, Thames H, Ajani JA, Drewinko B (1985) Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays. J Cancer Res Clin Oncol 109: 130-134